Treatment of Type 1 Diabetes Mellitus by Increasing Human Leukocyte Antigen-G Expression with Polymeric Nanoparticles Using Gene Therapy


Type 1 Diabetes Mellitus in most cases is an autoimmune disease. Insulin injection is just a symptom therapy that is bothering for the patient and usually does not correct the blood glucose level appropriately. Attempts to replace the lost pancreatic cells such as islet and stem cell transplantation were not permanent cures because the original problem which was autoimmunity still existed. On the other hand, while using allogenic cells, immune system rejects the foreign cells. We suppose an approach to use the cells that are not affected by autoimmunity and can divide and replace the pancreatic β cells. Human Leukocyte Antigen-G (HLA-G) protein suppresses the im-mune system by affecting the T cells and natural killer cells and some other immune system cells and is responsible for keeping the fetus from maternal immune system in pregnancy. Autologous mesenchymal stem cells and insulin producing cells are candi-date cells to be transfected with HLA-G gene. Transplantation of these genetically modified autologous stem cells to the patient leads to permanent production of β cells that are out of the reach of the immune system. As they are autologous cells, there is no fear of rejection. Nanoparticle based gene delivery is the desired procedure since there is no fear of tumor genesis with this method.

Download full-text


Available from: Mohsen Khosravi